MetaVia is trading 5.22% up at $1.21 in pre-market, with no confirmed company-specific catalyst identified for the October 28 move.
- The latest located company announcement was the October 13 appointment of Sarah Browne as chief medical officer.
- Broader markets were mixed and do not clearly explain the move. The company previously indicated topline data from its higher-dose DA-1726 Phase 1 study is anticipated in Q4 2026; no new readout was identified.